Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, committed to advancing innovative therapies for central nervous system (CNS) disorders and associated conditions. The company is focused on developing a robust pipeline of candidates aimed at addressing critical unmet medical needs in pain management and psychiatric disorders, utilizing cutting-edge research and technology. By prioritizing patient outcomes, Relmada is strategically positioned to become a significant contributor in the rapidly evolving CNS therapeutics market, potentially offering valuable solutions for patients and healthcare providers alike.